

## Vasor: accurately predicting single amino acid substitution impact within the MDR3 protein

## Annika Behrendt<sup>1</sup>, Pegah Golchin<sup>2</sup>, Filip Koenig<sup>1</sup>, Daniel Mulnaes<sup>1</sup>, Amelie Stalke<sup>3,4</sup>, Carola Dröge<sup>5,6</sup>, Verena Keitel<sup>5,6</sup>, Holger Gohlke<sup>1,7</sup>

1 Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf; 2 Department of Electrical Engineering and Information Technology, Technische Universität Darmstadt; 3 Department of Human Genetics, Hannover Medical School; 4 Department of Pediatric Gastroenterology and Hepatology, Division of Kidney, Liver and Metabolic Diseases, Hannover Medical School; 5 Department for Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Otto von Guericke University Magdeburg; 6 Department for Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Medical Faculty, Heinrich Heine University Düsseldorf; 7 John-von-Neumann-Institute for Computing (NIC), Jülich Supercomputing Centre (JSC), Institute of Biological Information Processing (IBI-7: Structural Biochemistry), and Institute of Bio- and Geosciences (IBG-4: Bioinformatics), Forschungszentrum Jülich

Multidrug Resistance protein 3 (MDR3) is an essential hepatobiliary transport protein. MDR3 flops phosphatidylcholine (PC) from the inner to the outer membrane leaflet, where PC can get extracted into primary bile. Dysfunction of MDR3 thus can disturb the carefully regulated bile homeostasis. Phenotypically, this imbalance can result in transient manifestations such as intrahepatic cholestasis of pregnancy to severe forms of progressive familial intrahepatic cholestasis 3 (PFIC3), leading to liver failure in affected children. Genetically, the majority of disease-causing MDR3 variants are missense variations within the MDR3-coding *ABCB4* gene.



However, assessing the impact of variants identified in sequenced patients continues to be a challenge for clinicians and researchers.

Key protein players of bile homeostasis can be affected in PFIC diseases.

Aim: Predict effect of missense variants in MDR3 identified in patients into the categories benign and pathogenic



Our dataset: 364 variants (279 benign, 85 pathogenic)



Variant assessor of MDR3 (Vasor) performance compared to established predictors



Calculation of every possible substitution



Fig. 2: A: ROC, B: coverage, and C: precision-recall curves of predictors on dataset.

Vasor's output: Probability of

pathogenicity of variants

amino acid substitution.

Fig. 4: A: Heatmap, B: sec. structure, C: motifs and domains of MDR3



Making Vasor easily accessible: Implementing a webserver

Clinicians and researchers can enter their variant of interest at https://cpclab.uni-duesseldorf.de/mdr3 predictor/



## Prediction output with probability of pathogenicity value and visualization of variant site within MDR3 protein structure



## References & Funding

Behrendt A, Golchin P, König F, Mulnaes D, Stalke A, Dröge C, Keitel V, Gohlke H. Vasor: Accurate prediction of variant effects for amino acid substitutions in MDR3. Hepatol. Commun. 2022, DOI: 10.1002/hep4.2088.

hhu.de

This study was supported by the BMBF through HiChol (01GM1904A, 01GM1904B) and, in part, InCelluloProtStruct (031L0182). We gratefully acknowledge the computing time granted by the John von Neumann Institute for Computing (NIC).

Annika.Behrendt@hhu.de | CPClab | https://cpclab.uni-duesseldorf.de/mdr3\_predictor/